Bridging testing gaps by enabling an FDA-cleared IVD tumor profiling precision oncology test within your local community setting

Implementing PGDx elio tissue complete reduces turnaround times, supporting prompt clinical decision-making and timely interventions for patients within the local community 

By minimizing reliance on external labs, the center gains enhanced control over testing operations, leading to streamlined processes and improved patient care 

The transition to PGDx elio tissue complete empowers oncologists with detailed information for personalized treatment strategies, improves clinical pass rates and fosters a multidisciplinary approach through molecular tumor boards